09 Dec, 2019 10:56 AM
PERTH, AUSTRALIA – 9 December 2019: SUDA Pharmaceuticals Ltd (ASX:SUD), a leader in oromucosal drug delivery, is pleased to announce that it has entered into a feasibility agreement with SANOF...read more
06 Dec, 2019 10:25 AM
Sienna Cancer Diagnostics Ltd (ASX:SDX) (“Sienna” or “the Company”), a medical technology company developing and commercialising innovative IVD tests, is pleased to announce ...read more
05 Dec, 2019 08:25 AM
SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oro-mucosal drug delivery, today announces that it has entered into a fully-funded, feasibility study and option agreement with Laboratorios Ordesa, ...read more
29 Nov, 2019 05:45 PM
The suspension of trading in the securities of Sienna Cancer Diagnostics Limited ('SDX') will be lifted immediately, following the release by SDX of an announcement regarding a capital raising...read more
29 Nov, 2019 05:43 PM
Sienna to raise up to approximately $4.2 million, before costs, via a share placement and rights issue at 3.5 cents per share.
To read more, download the attached PDF.
28 Nov, 2019 10:11 AM
The securities of Sienna Cancer Diagnostics Limited ('SDX') will be suspended from quotation immediately under Listing Rule 17.2, at the request of SDX, pending the release of an announcement ...read more
27 Nov, 2019 11:13 AM
Michael Baker joins SUDA Pharmaceuticals from the leading Australian life science fund, Bioscience Managers, where he was based from 2017. As an Investment Manager, he was responsible for deal sourc...read more
18 Nov, 2019 11:11 AM
SUDA Pharmaceuticals (ASX:SUD), a leader in oro-mucosal drug delivery, is pleased to advise that it has received a refund of $927,970 from the Australian Taxation Office under the R&D Tax In...read more
